trial failure
Jazz and PharmaMar’s Zepzelca combo misses main goal in small cell lung cancer sub-population
December 3, 2020Research and Development PharmaMar, jazz pharma, trial failure
Jazz Pharma and PharmaMar have revealed that their jointly-developed therapy Zepzelca (lurbinectedin), when combined with doxorubicin, fell short of its …
Roche’s entrolizumab disappoints at Phase 3 in moderately to severely active ulcerative colitis
August 11, 2020Manufacturing and Production, Research and Development Roche, etrolizumab, trial failure, ulcerative colitis
Roche has voiced its disappointment after its investigational therapy etrolizumab showed “mixed results” as a treatment for moderately to severely …
Acadia’s pimavanserin falls short at Phase 3 in major depressive disorder
July 21, 2020Manufacturing and Production, Research and Development Acadia Pharmaceuticals, major depressive disorder, phase 3, trial failure
Acadia Pharmaceuticals has lifted the lid on new Phase 3 for its therapy pimavanserin, revealing that the drug unfortunately failed …
MSD’s Keytruda misses the mark at Phase 3 in advanced bladder cancer
June 11, 2020Research and Development MSD< Keytruda, bladder cancer, pharma, trial failure
MSD has announced the disappointing findings that its anti-PD-1 immunotherapy Keytruda (pembrolizumab), when used either alone or combined with chemotherapy, …
Bavencio Phase 3 head and neck cancer trial terminated
March 16, 2020Research and Development, Sales and Marketing Bavencio, Cancer, EMD Serono, Merck KGaA, Pfizer, trial failure
Merck KGaA, its biopharma division EMD Serono, and Pfizer have announced their decision to terminate their ongoing Phase 3 trial …
AstraZeneca’s cediranib combo misses main goal in platinum-sensitive relapsed ovarian cancer
March 13, 2020Medical Communications, Research and Development AstraZeneca, cediranib, lynparza, pharma, trial failure
Newly revealed Phase 3 data has shown that AstraZeneca’s oral vascular endothelial growth factor receptor (VEGFR) inhibitor cediranib, when combined …
Phase 3 failure for AstraZeneca’s Imfinzi combo in unresectable metastatic bladder cancer
March 6, 2020Medical Communications, Research and Development AstraZeneca, Cancer, Imfinzi, bladder cancer, pharma, trial failure
New Phase 3 has been released by AstraZeneca, showing that the PD-L1 inhibitor Imfinzi (durvalumab), when combined with tremelimumab, failed …
Eli Lilly’s solanezumab fails at Phase 2/3 in early-onset Alzheimer’s disease
February 11, 2020Manufacturing and Production Alzheimer's Eli Lilly, pharma, trial failure
In another blow to Alzheimer’s research, it has emerged that a study investigating Eli Lilly’s solanezumab in the treatment of …
Roche’s Tecentriq falls short as an adjuvant monotherapy in muscle-invasive urothelial cancer
January 24, 2020Medical Communications, Sales and Marketing Cancer, Roche, pharma, tecentriq, trial failure
Roche has released an update on the development of its immunology Tecentriq (atezolizumab), making it known that the drug failed …
Incyte’s drug stumbles at Phase 3 in treatment-naive acute graft-versus-host disease
January 6, 2020Research and Development, Sales and Marketing Incyte, pharma, trial failure
Drugmaker Incyte has made it known that its selective JAK1 inhibitor therapy itacitinib fell short at Phase 3 in the …
Novartis pulls fevipiprant development in asthma following trial failure
December 16, 2019Research and Development, Sales and Marketing Fevipiprant, Novartis, asthma, pharma, trial failure
Novartis has made it known that its DP2 receptor antagonist fevipiprant failed at Phase 3 to show clinically relevant levels …
Biogen terminates gosuranemab in progressive surpanuclear palsy following Phase 2 failure
December 16, 2019Research and Development, Sales and Marketing Biogen, pharma, trial failure
Biogen has revealed its intention to shut down further development of gosuranemab after results of a Phase 2 study showed …
Sage Therapeutics’ depression drug falls short at Phase 3
December 6, 2019Medical Communications, Research and Development Sage Therapeutics, major depressive disorder, pharma, trial failure
Sage Therapeutics has announced that its candidate SAGE-217 flopped in Phase 3 trials investigating its efficacy in symptom reduction for …
Halozyme culls staff by 55% following Phase 3 metastatic pancreas cancer failure
November 6, 2019Manufacturing and Production, Research and Development Halozyme, pharma, trial failure
Halozyme Therapeutics has announced it is to cull its workforce by more than half in the wake of the news …
Catalyst’s lead candidate Firdapse falls short in Congenital Myasthenic Syndromes
October 31, 2019Research and Development Catalyst Pharmaceuticals, FDA, firdapse, pharma, trial failure
Catalyst Pharmaceuticals has made it known that its lead product Firdapse (Amifampridine Phosphate) fell short of its primary endpoint in …
